Start of evaluation and selection of Glucox Biotech' lead drug candidates, GLX009 and GLX010 for efficacy tests and improvements in glucose uptake and insulin sensitivity in muscle cells.
Proof of improved insulin sensitivity in insulin resistant muscle cells by treatment with Glucox Biotech' model drug candidate.